| INTRODUC TI ON
The rapid aging of the global population is resulting in an increasing prevalence of mild cognitive impairment (MCI) and dementias. 1, 2 Age is a key risk factor for dementia and Alzheimer's disease (AD) 1 ;
after the age of 65 years, the prevalence of dementia doubles with every five additional years. 2 Prevalence is higher among women than men, largely because women tend to live longer. 2 In 2018, the number of individuals worldwide with dementia was estimated to be 50 million. This number has been projected to increase exponentially to 82 million by 2030, and to 152 million by 2050. 4 In high-income countries, estimates of dementia prevalence are around 5%-10% in the population aged 65 years or older 2 ; however, evidence suggests the prevalence in such countries may be reaching a plateau. 5, 6 In the developing world, however, the increasingly maturing population is expected to be mirrored by a continued rise in the prevalence of dementia, 3, 7, 8 with an estimated 68% of dementia cases expected to be found in low-to-middle income countries by the year 2050. 3 Asian data indicate a crude estimated dementia prevalence of 4.7% in the over-60 population; although there is country-to-country variation. 3, 8 National reports of dementia prevalence in various Asian countries range between approximately 2%-13%, 8, 9 and this is expected to rise dramatically in coming years. 8 Cerebrovascular disease (CVD) frequently coexists with AD. In Asia, AD + CVD accounts for up to 20% of all dementia cases, 9 and there is some evidence for a higher prevalence of AD + CVD in the Asian region compared with Western populations. 10 Globally, but also in Asia, AD + CVD is thought to be underdiagnosed, primarily due to lack of awareness resulting from a lack of defined diagnostic criteria, but also due to the high cost of investigations, a lack of adequate diagnostic facilities, and other resource constraints. 9 It has been suggested that some Asian epidemiology studies may be influenced by "survivor bias" due to a high proportion of early deaths. 9 Epidemiology study methodologies and findings are also heterogeneous; among dementia patients across Asia, estimated proportions of dementia patients with AD + CVD range between 7% (Sri Lanka) and 50% (Japan). 9 Dementias place an appreciable burden on patients, their families, and the healthcare system. Quality of life (QoL) is decreased for patients as well as for their families and caregivers, and a severe cost burden also results from long-term medication use, hospitalization, and home-based healthcare.
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| Definitions and symptoms
Mild cognitive impairment is understood to be a neurocognitive state between normal cognitive aging and dementia, and can be an early manifestation of, and a risk factor for, AD or other neurodegenerative disorders. 12, 13 MCI is not linked to any specific etiology, 13 but in the context of AD biomarkers, MCI is considered to be a prodromal stage of AD dementia. 12 MCI is characterized by mild impairment 
K E Y W O R D S
Alzheimer disease, cerebrovascular disease, dementia, EGb 761 ® , Ginkgo biloba in one or more cognitive domains, but, in contrast to overt AD dementia, no significant social or occupational impairments are present; individuals are generally able to maintain independence in daily functioning with minimal assistance. 12, 14, 15 Clinically overt dementia has a spectrum ranging from mild to severe. 15 Diagnosis involves clinical assessment, neuropsychological evaluation, and often neuroimaging. 9 Core clinical criteria for all-cause dementia, based on DSM-5 criteria for neurocognitive disorders, include cognitive impairments and behavioral symptoms that interfere with functioning and activities of daily living (ADL). Typical cognitive symptoms may include impairments in complex attention, executive function, learning and memory, language function, perceptual motor function, and social cognition. 15 Noncognitive behavioral and psychological symptoms of dementia (BPSD), also known as neuropsychiatric symptoms (NPS), are observed across the severity spectrum of dementia, 16 and can include changes in personality or usual conduct, anxiety, agitation, elation, irritability, apathy/indifference, depression/dysphoria, disinhibition, aberrant motor behavior, sleep or appetite changes, and hallucinations or delusions. 15, 16 The term "AD dementia" specifically refers to a clinical syndrome arising secondary to the pathophysiological process that leads to AD. 15 AD and vascular dementia (VaD) are considered to be the most common forms of dementia, 9 but more recently, attention has focused on the co-existence of AD and CVD. 18, 19 AD and VaD may be considered to be a disease continuum, with pure AD at one end of the spectrum, VaD at the other, and AD with concomitant CVD comprising the majority of cases. 18, 21, 22 AD and CVD contribute independently, but additively, to the risk of dementia.
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It is important to distinguish between AD, VaD, and AD + CVD, because of differences in clinical course and cognitive profiles, and differential treatment responses. 9 Diagnosis of AD + CVD can be made when (a) clinical signs of AD dementia are accompanied by evidence of CVD (vascular lesions) on brain imaging; or (b) dementia clinically presenting as sudden-onset, is accompanied by biomarker evidence of AD such as amyloid plaques on positron emission tomography. 9 The neuroimaging hallmarks of CVD include chronic lacunes, white matter hyperintensities (WMH), perivascular spaces, and microbleeds. 9 CVD has been demonstrated to be a risk factor for progression from MCI to AD. 24 WMH have also been shown to be independently associated with BPSD. 25 
| Management options
Goals of dementia treatment are stabilization or slowing of disease progression, reduction in psychological and behavioral symptoms, improvement of QoL, and reduction of caregiver burden. The Ginkgo biloba special extract, EGb 761 ® has also been used widely in the treatment of cognitive disorders, including AD and AD + CVD. 26, 27 
| ME THODS
The Asian Clinical Expert Group on Neurocognitive Disorders consists of twenty members including neurologists, geriatricians, psychiatrists and a pharmacist, from around the Asia region. There was also involvement of an expert advisory member from Germany. presentations on key published findings were delivered by experts in the field. All proposed statements were then discussed in depth, and when necessary, polling of Expert Group members was carried out to choose or formulate statements that were accepted unanimously or by majority vote.
This document is intended as a collection of consensus recommendations only, and is not designed to be used as a treatment algorithm. Experts' clinical opinions were based on the available data, and were unrelated to different regulatory classifications in respective countries.
| RE SULTS
The Expert Group identified English language articles relevant to the use of EGb 761 ® in MCI, AD, VaD, and BPSD in the literature. The
Group also identified a number of salient aspects relating to the use of EGb 761 ® in clinical practice, and formed specific consensus recommendations based on the available evidence (Table 1) . Key trials evaluating EGb 761 ® are summarized in Table 2 , and key meta-analyses are discussed below.
| Efficacy of EGb 761 ® in placebo-

controlled trials
Older placebo-controlled clinical trials have been heterogeneous in study design, EGb 761 ® dosage, and effect sizes, but overall have shown modest improvement in cognitive function and ADL. 27, 42, 43 However, more recently, three multicenter, randomized, doubleblind, placebo-controlled trials of comparable design were conducted in patients aged ≥50 years with possible/probable AD or The GuidAge trial included 2,850 French primary care patients with memory complaints, who were prospectively followed up over five years. 51 The GEM study (USA) randomized a total of 3069 individuals aged ≥75 years with normal cognition or MCI at baseline, and assessed them every six months, with a median follow-up of 6.1 years. 52 Neither study demonstrated a clear preventative effect in initial analyses. 51, 52 However, a post hoc analysis of the GuidAge study demonstrated a possible late effect of EGb 761 ® when a more appropriate statistical test was applied. 53 Further studies are warranted.
| EGb 761 ® safety
EGb 761 ® has been shown to have a positive risk-benefit profile. 42, 47 Studies have consistently shown no significantly increased overall risk of adverse events (AEs) compared with placebo. 
TA B L E 1 (Continued)
Classes of recommendation ® also improved ADL: 0.14-point improvement in GERRI score vs placebo (P = 0.004); 37% vs 23% of patients, respectively, improved on the GERRI scale (P = 0.003) Kanowski (1996) Importantly, EGb 761 ® does not appear to increase overall bleeding risk, 40, 58, 59 nor to interact with common antiplatelet agents or anticoagulants. 62, 63 However, these studies were performed in young, healthy volunteers, and it is unclear how accurately the data can be 
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